Table 3.

Clinical trials of PARP inhibitors as maintenance in the front-line setting.

Study	Phase	Population	Study Arm	Control Arm	Results
SOLO-1 NCT01844986	III	HGSOC/endometrioid (or FP/PPC) FIGO III–IV BRCAm CR/PR platinum-based chemotherapy	Olaparib 300 mg BID	Placebo	PFS NR vs. 13.8 m HR 0.30 (95% CI 0.23–0.41)
PRIMA NCT02655016	III	HGSOC/endometrioid (or FP/PPC) FIGO III–IV Regardless of BRCA status CR/PR platinum-based chemotherapy	Niraparib 300 mg daily	Placebo	ITT PFS 13.8 vs. 8.2 m HR 0.62 (95% CI 0.50–0.76) HRD PFS 21.9 vs. 10.4 m HR 0.43 (95% CI 0.31–0.59) BRCAmut 0.40 (95% CI, 0.27–0.62)
PAOLA-1 NCT02477644	III	HGSOC/endometrioid/other epithelial non-mucinous (or FP/PPC) FIGO IIIB, IIIC or IV gBRCAm/BRCAwt if HGS CR/PR platinum-based chemotherapy	Olaparib 300 mg BID + bevacizumab 15 mg/kg/3 wks	Placebo + Bevacizumab 15 mg/kg/3 wks	ITT PFS 22.1 vs. 16.6 m HR 0.59 (95% CI 0.49–0.72) BRCAmut HR 0.31 (95% CI 0.20–0.47)
VELIA NCT02470585	III	HGSOC OC (or FP/PPC) FIGO III–IV	Paclitaxel-carboplatin-veliparib (150 mg BID-2 weeks 400 mg BID) → veliparib	Paclitaxel-carboplatin-placebo → placebo	ITT PFS: 23.5 vs. 17.3 m HR 0.68 (95% CI 0.56–0.83) BRCAmut PFS: 34.7 vs. 22 m HR 0.44 (95% CI 0.28–0.68)